ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other Events
Item 8.01 Other Events.
issued a joint press release titled “Luspatercept Phase 2 Data
Presented at the 14th International Symposium on Myelodysplastic
Syndromes.”
Current Report on Form 8-K and is incorporated herein by
reference.
|
Exhibit Number
|
Description of Exhibit
|
|
|
99.1
|
Press release of Acceleron Pharma Inc. and Celgene
Corporation dated May 6, 2017 |
About ACCELERON PHARMA INC. (NASDAQ:XLRN)
Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company’s pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development. ACCELERON PHARMA INC. (NASDAQ:XLRN) Recent Trading Information
ACCELERON PHARMA INC. (NASDAQ:XLRN) closed its last trading session down -0.03 at 28.24 with 642,556 shares trading hands.
